Niraparib provides new hope for ovarian cancer patients

Ovarian cancer patients may now be able to use niraparib (a PARP inhibitor) to extend the time they have before the disease gets worse. We call this progression-free survival. Snappy Science looks at new research from the PRIMA trial that is adding to the encouraging body of evidence providing hope for those with ovarian cancer.

PRIMA Trial: lnkd.in/gDA4Rf3

NOVA trial: lnkd.in/g3riKxB

Subscribe now! ---❯ vod.strms.net/s/UCbSpotYW2sAbpRpYq_5nAEg
Subscriber goal ---❯ ||||||||||||||| 195% ||||||||||||||| 390/200
Thanks to Snappy Science's newest subscriber: Harold Ginn